Mineralys Therapeutics Inc (NASDAQ:MLYS) has a beta value of 1.44 and has seen 0.25 million shares traded in the last trading session. The company, currently valued at $509.64M, closed the last trade at $10.24 per share which meant it gained $0.04 on the day or 0.39% during that session. The MLYS stock price is -65.14% off its 52-week high price of $16.91 and 16.21% above the 52-week low of $8.58. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.29 million shares traded. The 3-month trading volume is 225.57K shares.
The consensus among analysts is that Mineralys Therapeutics Inc (MLYS) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight.
Mineralys Therapeutics Inc (NASDAQ:MLYS) trade information
Sporting 0.39% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the MLYS stock price touched $10.24 or saw a rise of 7.66%. Year-to-date, Mineralys Therapeutics Inc shares have moved -16.82%, while the 5-day performance has seen it change 4.38%. Over the past 30 days, the shares of Mineralys Therapeutics Inc (NASDAQ:MLYS) have changed 4.17%. Short interest in the company has seen 1.86 million shares shorted with days to cover at 7.36.
Wall Street analysts have a consensus price target for the stock at $30, which means that the shares’ value could jump 65.87% from current levels. The projected low price target is $30.0 while the price target rests at a high of $30.0. In that case, then, we find that the current price level is -192.97% off the targeted high while a plunge would see the stock gain -192.97% from current levels.
Mineralys Therapeutics Inc (MLYS) estimates and forecasts
The company’s shares have gained 12.16% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -170.42% over the past 5 years. Earnings growth for 2025 is a modest -7.97% while over the next 5 years, the company’s earnings are expected to decrease by -2.10%.
MLYS Dividends
Mineralys Therapeutics Inc is expected to release its next earnings report in March this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Mineralys Therapeutics Inc (NASDAQ:MLYS)’s Major holders
Insiders own 2.52% of the company shares, while shares held by institutions stand at 105.48% with a share float percentage of 108.21%. Investors are also buoyed by the number of investors in a company, with Mineralys Therapeutics Inc having a total of 155.0 institutions that hold shares in the company.
Also the top two Mutual Funds that are holding company’s shares are iShares Russell 2000 ETF and Vanguard Total Stock Market Index Fund. As of Nov 30, 2024, the former fund manager holds about 1.62% shares in the company for having 807.86 shares of worth $8.27 million while later fund manager owns 784.65 shares of worth $8.03 million as of Sep 30, 2024, which makes it owner of about 1.58% of company’s outstanding stock.
